These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 27463974)

  • 81. Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers.
    Hampel H; Broich K
    J Nutr Health Aging; 2009 Apr; 13(4):373-5. PubMed ID: 19300885
    [TBL] [Abstract][Full Text] [Related]  

  • 82. An overview of circulating cell-free microRNAs as putative biomarkers in Alzheimer's and Parkinson's Diseases.
    Batistela MS; Josviak ND; Sulzbach CD; de Souza RL
    Int J Neurosci; 2017 Jun; 127(6):547-558. PubMed ID: 27381850
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Preliminary Study of hsa-mir-626 Change in the Cerebrospinal Fluid in Parkinson's Disease.
    Qin LX; Tan JQ; Zhang HN; Tang JG; Jiang B; Shen XM; Guo JF; Tan LM; Tang B; Wang CY
    Neurol India; 2021; 69(1):115-118. PubMed ID: 33642281
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The Concept of Prodromal Parkinson's Disease.
    Mahlknecht P; Seppi K; Poewe W
    J Parkinsons Dis; 2015; 5(4):681-97. PubMed ID: 26485429
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.
    Lista S; Zetterberg H; Dubois B; Blennow K; Hampel H
    J Neurol; 2014 Jun; 261(6):1234-43. PubMed ID: 24807087
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.
    Halperin I; Morelli M; Korczyn AD; Youdim MB; Mandel SA
    Neurotherapeutics; 2009 Jan; 6(1):128-40. PubMed ID: 19110204
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cognitive interventions in Alzheimer's and Parkinson's diseases: emerging mechanisms and role of imaging.
    Vemuri P; Fields J; Peter J; Klöppel S
    Curr Opin Neurol; 2016 Aug; 29(4):405-11. PubMed ID: 27213773
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer's Disease and Parkinson's Disease.
    Pawlik P; Błochowiak K
    Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33671562
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology.
    Maarouf CL; Beach TG; Adler CH; Malek-Ahmadi M; Kokjohn TA; Dugger BN; Walker DG; Shill HA; Jacobson SA; Sabbagh MN; Roher AE;
    Biomark Insights; 2013; 8():19-28. PubMed ID: 23533154
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease.
    Hossein-Nezhad A; Fatemi RP; Ahmad R; Peskind ER; Zabetian CP; Hu SC; Shi M; Wahlestedt C; Zhang J; Faghihi MA
    J Parkinsons Dis; 2016; 6(1):109-17. PubMed ID: 26889637
    [TBL] [Abstract][Full Text] [Related]  

  • 92. T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer's Disease: Potential Pools of New Biomarkers.
    Mietelska-Porowska A; Wojda U
    J Immunol Res; 2017; 2017():4626540. PubMed ID: 28293644
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.
    Fu Y; Zhao D; Yang L
    J Mol Neurosci; 2014 Dec; 54(4):739-47. PubMed ID: 24961342
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Towards early disease modification of Parkinson's disease: a review of lessons learned in the Alzheimer field.
    Smedinga M; Darweesh SKL; Bloem BR; Post B; Richard E
    J Neurol; 2021 Feb; 268(2):724-733. PubMed ID: 32809153
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies.
    Ciceri F; Rotllant D; Maes T
    Curr Pharm Des; 2017; 23(5):839-857. PubMed ID: 28120717
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Ultrasensitive detection of blood biomarkers of Alzheimer's and Parkinson's diseases: a systematic review.
    Singh K; Cheung BM; Xu A
    Biomark Med; 2021 Dec; 15(17):1693-1708. PubMed ID: 34743546
    [No Abstract]   [Full Text] [Related]  

  • 97. Recent progress in neurodegenerative disorder research in China.
    Zhou J
    Sci China Life Sci; 2010 Mar; 53(3):348-355. PubMed ID: 20596930
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies.
    Kang JH; Ryoo NY; Shin DW; Trojanowski JQ; Shaw LM
    Korean J Physiol Pharmacol; 2014 Dec; 18(6):447-56. PubMed ID: 25598657
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease.
    McGhee DJ; Ritchie CW; Zajicek JP; Counsell CE
    BMC Neurol; 2016 Jun; 16():92. PubMed ID: 27312378
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Biomarkers for Parkinson's Disease: Recent Advancement.
    Lotankar S; Prabhavalkar KS; Bhatt LK
    Neurosci Bull; 2017 Oct; 33(5):585-597. PubMed ID: 28936761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.